

Combination of Mirabegron and Solifenacin VS Mirabegron alone for management of OAB

Dr. Mubasher Saeed Pansota , Dr. Muhammad Hamza Ejaz, Dr. Asma Bano Ali

Background

Until now, the problem of treatment for OAB still remains challenging. Thus, the introduction of totally new drug mirabegron, which is a beta 3 - adrenoreceptor agonist, has turned out to be much in demand among specialists engaged in OAB. In clinical practice, most OAB patients are initiated on an antimuscarinic, which is escalated to a higher dose or switched to an alternative antimuscarinic or the beta 3- adrenoceptor agonist, mirabegron.

Aims & Objectives

To compare the efficacy of combination of mirabegron and solifenacin with mirabegron alone for overactive bladder in women.

Materials & Methods


A total of 480 women having overactive bladder, 20 to 50 years of age were included. Patients with UTI, Pregnancy, Bladder stone, Pelvic malignancy, Spinal injury, Multiple sclerosis, Parkinson disease, Diabetic neuropathy were excluded. Patients in Group A took mirabegron 25 mg + solifenacin 5 mg once daily for 12 weeks and in Group B, patients took mirabegron 25 mg once daily for 12 weeks. Urinary incontinence was assessed at baseline and after 12 weeks of treatment on the base of history. OABS score at baseline and after 12 weeks of treatment. Patients were followed for 12 weeks by taking patient's contact number. Efficacy was assessed as per operational definition after 12 weeks of treatment.

Result

Mean OABS score at baseline and after 12 weeks in group A was 10.33 ± 3.12 and 4.43 ± 1.32 and in group B was 10.13 ± 2.98 and 6.87 ± 2.76 respectively. Efficacy of Group A (combination of mirabegron and solifenacin) was seen in 143 (59.58%) patients while in Group B (mirabegron alone) was seen in 117 (48.75%) patients with p-value of 0.017.

Conclusion

This study concluded that combination of mirabegron and solifenacin is better than the mirabegron alone for management of overactive bladder in women.



References

- Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee K, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int., 2010;21; 28(6): 896-901.
- Makhani A, Thake M, Gibson W. Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient. Clin Interv Aging., 2020; 15: 575-81. 7; 120(4): 562-75.